...MRX-I to treat acute bacterial skin and skin structure infections (ABSSSIs). In 2012, MicuRx and Shanghai Zhangjiang Biomedical Industry Venture Capital...

...and 800 mg oral MRX-I vs. linezolid in about 200 patients. In 2012, MicuRx and Shanghai Zhangjiang Biomedical Industry Venture Capital...

..."shortly" and a Phase II trial in the U.S. in 2H14. Last year, MicuRx and Shanghai Zhangjiang Biomedical Industry Venture Capital...

...MicuRx and Shanghai Zhangjiang Biomedical Industry Venture Capital launched Shanghai MengKe Pharmaceuticals Inc., a JV to develop and commercialize MicuRx's antibiotic...